pISSN 1226-6051
eISSN 2508-786X

Table. 1.

Table. 1.

Demographic and Clinical Characteristics of Osteoporosis Treatments Prescribed Patients, 2018

(unit: person) Anti-resorptives Bone-forming


Bisphosphonates SERMs Denosumab Calcitonin Total Anti-resorptives Teriparatide
Total, n(%) 38,802(86.6%) 6,242(13.9%) 931(2.1%) 1,394(3.1%) 44,697(99.3%) 296(0.7%)
Age group, n(%)
50-64 11,224(28.9%) 2,251(36.1%) 279(30.0%) 268(19.2%) 13,304(29.8%) 43(14.5%)
65-74 14,219(36.7%) 2,235(35.8%) 335(36.0%) 493(35.4%) 16,293(36.5%) 95(32.1%)
≥75 13,359(34.4%) 1,756(28.1%) 317(34.1%) 633(45.4%) 15,100(33.8%) 158(53.4%)
Gender, n(%)
Male 2,722(7.0%) 6(0.1%) 67(7.2%) 175(12.6%) 2,874(6.4%) 25(8.5%)
Female 36,080(93.0%) 6,236(99.9%) 864(92.8%) 1,219(87.5%) 41,823(93.6%) 271(91.6%)
Health insurance type, n(%)
National health insurance 35,217(90.8%) 5,759(92.3%) 840(90.2%) 1,235(88.6%) 40,663(91.0%) 273(92.2%)
Medical aid, veterans etc. 3,585(9.2%) 483(7.7%) 91(9.8%) 159(11.4%) 4,034(9.0%) 23(7.8%)
Patients with osteoporotic fractures, n(%)
No fracture 33,812(87.1%) 5,480(87.8%) 765(82.2%) 1,030(73.9%) 38,982(87.2%) 107(36.2%)
Fracture 4,990(12.9%) 762(12.2%) 166(17.8%) 364(26.1%) 5,715(12.8%) 189(63.9%)
Fracture site, n(%)
Vertebral 3825(76.7%) 536(70.3%) 131(78.9%) 297(81.6%) 4,335(75.9%) 156(82.5%)
Hip 181(3.6%) 18(2.4%) 5(3.0%) 18(5.0%) 205(3.6%) 6(3.2%)
Distal radius 694(13.9%) 150(19.7%) 17(10.2%) 30(8.2%) 825(14.4%) 9(4.8%)
Humerus 149(3.0%) 28(3.7%) 6(3.6%) 5(1.4%) 178(3.1%) 5(2.7%)
Multiple Sites 141(2.8%) 30(3.9%) 7(4.2%) 14(3.9%) 172(3.0%) 13(6.9%)

* Comparisons (bone-forming agents vs. anti-resorptives) that are statistically significant at p<0.05 are noted by .

* Patients and prescriptions can be counted in more than one category

Abbreviation: SD, standard deviation; SERMs, Selective Estrogen Receptor Modulators

Korean J Clin Pharm 2021;31:27-34 https://doi.org/10.24304/kjcp.2021.31.1.27
© 2021 Korean J Clin Pharm